Literature DB >> 25052825

Regulatory T cells enhance mesenchymal stem cell survival and proliferation following autologous cotransplantation in ischemic myocardium.

Yifu Zhou1, Avneesh K Singh2, Robert F Hoyt2, Suna Wang2, Zuxi Yu2, Timothy Hunt2, Bogdan Kindzelski2, Philip C Corcoran2, Muhammad M Mohiuddin2, Keith A Horvath2.   

Abstract

OBJECTIVES: We sought to investigate if autologous freshly isolated regulatory T cells (Tregs) provide a protective and supportive role when cotransplanted with mesenchymal stem cells (MSCs).
METHODS: In a porcine model of chronic ischemia, autologous MSCs were isolated and expanded ex vivo for 4 weeks. Autologous Treg cells were freshly isolated from 100 mL peripheral blood and purified by fluorescence-activated cell sorting. MSCs and Treg cells were then cotransplanted into the chronic ischemic myocardium of Yorkshire pigs by direct intramyocardial injection (1.2 × 10(8) MSCs plus an average of 1.5 million Treg cells in 25 injection sites). Animals were killed 6 weeks postinjection to study the fate of the cells and compare the effect of combined MSCs + Treg cells transplantation versus MSCs alone.
RESULTS: The coinjection of MSCs along with Tregs was safe and no deleterious side effects were observed. Six weeks after injection of the cell combination, spherical MSCs clusters with thin layer capsules were found in the injected areas. In animals treated with MSCs only, the MSC clusters were less organized and not encapsulated. Immunofluorescent staining showed CD25+ cells among the CD90+ (MSC marker) cells, suggesting that the injected Treg cells remained present locally, and survived. Factor VIII+ cells were also prevalent suggesting new angiogenesis. We found no evidence that coinjections were associated with the generation of cardiac myocytes.
CONCLUSIONS: The cotransplantation of Treg cells with MSCs dramatically increased the MSC survival rate, proliferation, and augmented their role in angiogenesis, which suggests a new way for future clinical application of cell-based therapy. Published by Mosby, Inc.

Entities:  

Mesh:

Year:  2014        PMID: 25052825      PMCID: PMC4182951          DOI: 10.1016/j.jtcvs.2014.06.029

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  29 in total

1.  Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells.

Authors:  Andrea Facciabene; Xiaohui Peng; Ian S Hagemann; Klara Balint; Andrea Barchetti; Li-Ping Wang; Phyllis A Gimotty; C Blake Gilks; Priti Lal; Lin Zhang; George Coukos
Journal:  Nature       Date:  2011-07-13       Impact factor: 49.962

2.  Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI).

Authors:  Birgit Assmus; Volker Schächinger; Claudius Teupe; Martina Britten; Ralf Lehmann; Natascha Döbert; Frank Grünwald; Alexandra Aicher; Carmen Urbich; Hans Martin; Dieter Hoelzer; Stefanie Dimmeler; Andreas M Zeiher
Journal:  Circulation       Date:  2002-12-10       Impact factor: 29.690

3.  Hyaluronic acid-human blood hydrogels for stem cell transplantation.

Authors:  Connie Y Chang; Angel T Chan; Patrick A Armstrong; Hong-Chang Luo; Takahiro Higuchi; Iossif A Strehin; Styliani Vakrou; Xiaoping Lin; Sophia N Brown; Brian O'Rourke; Theodore P Abraham; Richard L Wahl; Charles J Steenbergen; Jennifer H Elisseeff; M Roselle Abraham
Journal:  Biomaterials       Date:  2012-08-13       Impact factor: 12.479

4.  Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans.

Authors:  Bodo E Strauer; Michael Brehm; Tobias Zeus; Matthias Köstering; Anna Hernandez; Rüdiger V Sorg; Gesine Kögler; Peter Wernet
Journal:  Circulation       Date:  2002-10-08       Impact factor: 29.690

5.  Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia.

Authors:  S Fuchs; R Baffour; Y F Zhou; M Shou; A Pierre; F O Tio; N J Weissman; M B Leon; S E Epstein; R Kornowski
Journal:  J Am Coll Cardiol       Date:  2001-05       Impact factor: 24.094

6.  Regulation of differentiation potential of human mesenchymal stem cells by intracytoplasmic delivery of coactivator-associated arginine methyltransferase 1 protein using cell-penetrating peptide.

Authors:  Junghyun Jo; Haengseok Song; Sang Gyu Park; Soo-Hong Lee; Jung-Jae Ko; Jong-Hyuk Park; Jaemin Jeong; Yong-Pil Cheon; Dong Ryul Lee
Journal:  Stem Cells       Date:  2012-08       Impact factor: 6.277

7.  Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model.

Authors:  Masashi Kawamura; Shigeru Miyagawa; Kenji Miki; Atsuhiro Saito; Satsuki Fukushima; Takahiro Higuchi; Takuji Kawamura; Toru Kuratani; Takashi Daimon; Tatsuya Shimizu; Teruo Okano; Yoshiki Sawa
Journal:  Circulation       Date:  2012-09-11       Impact factor: 29.690

8.  Preserving prostaglandin E2 level prevents rejection of implanted allogeneic mesenchymal stem cells and restores postinfarction ventricular function.

Authors:  Sanjiv Dhingra; Peng Li; Xi-Ping Huang; Jian Guo; Jun Wu; Anton Mihic; Shu-Hong Li; Wang-Fu Zang; Daniel Shen; Richard D Weisel; Pawan K Singal; Ren-Ke Li
Journal:  Circulation       Date:  2013-09-10       Impact factor: 29.690

9.  Efficient differentiation of human induced pluripotent stem cells generates cardiac cells that provide protection following myocardial infarction in the rat.

Authors:  Lee Carpenter; Carolyn Carr; Cheng Tao Yang; Daniel J Stuckey; Kieran Clarke; Suzanne M Watt
Journal:  Stem Cells Dev       Date:  2012-02-15       Impact factor: 3.272

10.  Cell-penetrating peptide (CPP)-conjugated proteins is an efficient tool for manipulation of human mesenchymal stromal cells.

Authors:  Junghyun Jo; Soomin Hong; Won Yun Choi; Dong Ryul Lee
Journal:  Sci Rep       Date:  2014-03-14       Impact factor: 4.379

View more
  15 in total

Review 1.  Mesenchymal Stem Cell-Based Therapy for Cardiovascular Disease: Progress and Challenges.

Authors:  Luiza Bagno; Konstantinos E Hatzistergos; Wayne Balkan; Joshua M Hare
Journal:  Mol Ther       Date:  2018-05-25       Impact factor: 11.454

Review 2.  Adenosine production: a common path for mesenchymal stem-cell and regulatory T-cell-mediated immunosuppression.

Authors:  Martha de Oliveira Bravo; Juliana Lott Carvalho; Felipe Saldanha-Araujo
Journal:  Purinergic Signal       Date:  2016-08-25       Impact factor: 3.765

Review 3.  Mesenchymal Stem Cell Transplantation for Ischemic Diseases: Mechanisms and Challenges.

Authors:  Thi-Tuong Van Nguyen; Ngoc Bich Vu; Phuc Van Pham
Journal:  Tissue Eng Regen Med       Date:  2021-04-21       Impact factor: 4.169

Review 4.  How to Improve the Survival of Transplanted Mesenchymal Stem Cell in Ischemic Heart?

Authors:  Liangpeng Li; Xiongwen Chen; Wei Eric Wang; Chunyu Zeng
Journal:  Stem Cells Int       Date:  2015-11-22       Impact factor: 5.443

5.  Mesenchymal stem cells that located in the electromagnetic fields improves rat model of Parkinson's disease.

Authors:  Majid Jadidi; Saeed Moghadas Biat; Hamid Reza Sameni; Manouchehr Safari; Abbas Ali Vafaei; Laya Ghahari
Journal:  Iran J Basic Med Sci       Date:  2016-07       Impact factor: 2.699

Review 6.  How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive.

Authors:  Alessandro Poggi; Serena Varesano; Maria Raffaella Zocchi
Journal:  Front Immunol       Date:  2018-02-19       Impact factor: 7.561

7.  Combination therapy with Treg and mesenchymal stromal cells enhances potency and attenuation of inflammation after traumatic brain injury compared to monotherapy.

Authors:  Henry W Caplan; Karthik S Prabhakara; Naama E Toledano Furman; Soheil Zorofchian; Akshita Kumar; Cecilia Martin; Hasen Xue; Scott D Olson; Charles S Cox
Journal:  Stem Cells       Date:  2020-12-31       Impact factor: 6.277

8.  Transplantation of vascular endothelial growth factor 165‑transfected endothelial progenitor cells for the treatment of limb ischemia.

Authors:  Sheng Wang; Zhong Chen; Xiaobin Tang; Hui Liu; Liao Yang; Yanyang Wang
Journal:  Mol Med Rep       Date:  2015-07-20       Impact factor: 2.952

9.  Preclinical Study of Cell Therapy for Osteonecrosis of the Femoral Head with Allogenic Peripheral Blood-Derived Mesenchymal Stem Cells.

Authors:  Qiang Fu; Ning Ning Tang; Qian Zhang; Yi Liu; Jia Chen Peng; Ning Fang; Li Mei Yu; Jin Wei Liu; Tao Zhang
Journal:  Yonsei Med J       Date:  2016-07       Impact factor: 2.759

Review 10.  Tyrosine kinase inhibitors and mesenchymal stromal cells: effects on self-renewal, commitment and functions.

Authors:  Adriana Borriello; Ilaria Caldarelli; Debora Bencivenga; Emanuela Stampone; Silverio Perrotta; Adriana Oliva; Fulvio Della Ragione
Journal:  Oncotarget       Date:  2017-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.